Data from EMA (European Medicines Agency) - Curated by Marshall Pearce - Last updated 10 November 2017

Indication(s)

- EMEND 40 mg hard capsules:
EMEND 40 mg is indicated for the prevention of postoperative nausea and vomiting (PONV) in adults.


- EMEND 80 mg hard capsules
- EMEND 125 mg hard capsules:

Prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in adults and adolescents from the age of 12.

EMEND 125 mg/80 mg is given as part of combination therapy


- EMEND 165 mg hard capsules:
Prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based cancer chemotherapy in adults.

Prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy in adults.

EMEND 165 mg is given as part of combination therapy.


- EMEND 125 mg powder for oral suspension:
Prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in children, toddlers and infants from the age of 6 months to less than 12 years.

EMEND powder for oral suspension is given as part of combination therapy.

Full Prescribing information

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Transplantation

Transplantation

See information on best practice in solid organ transplantation, and expert discussions on related hot topics.

Cushing's Syndrome

Cushing's Syndrome

Cushing’s syndrome shares symptoms such as hypertension, glucose intolerance and obesity with other common conditions – how can you confidently diagnose this rare disorder?

+ 2 more

Cystic Fibrosis

Cystic Fibrosis

View disease awareness information, treatment options and European Cystic Fibrosis Society best practice guidelines.

+ 1 more

Load more

Related Content

More information

Category Value
Agency product number EMEA/H/C/000527
Orphan designation No
Date First Approved 11-11-2003
Type Medicinal product subject to medical prescription
Marketing authorisation holder Merck Sharp & Dohme Ltd.